HSV-2 triggers upregulation of MALAT1 in CD4+ T cells and promotes HIV latency reversal

Carl A. Pierce, Lip Nam Loh, Holly R. Steach, Natalia Cheshenko, Paula Preston‐Hurlburt, Fengrui Zhang, Stephanie Stransky, Leah Kravets, Simone Sidoli, William M. Philbrick, Michel Nassar, Smita Krishnaswamy, Kevan C. Herold, Betsy C. HeroldJournal of Clinical Investigation 2023 · DOI

TL;DR

Researchers have discovered a molecular "alarm clock" that allows Herpes Simplex Virus type 2 (HSV-2) to wake up latent HIV-1. The study reveals that HSV-2 infection upregulates a long noncoding RNA called MALAT1, which strips away epigenetic silencing marks on the HIV genome, promoting viral reactivation even in "bystander" cells not directly infected by HSV-2.

What Problem Does This Paper Address?

It has long been known that HSV-2 and HIV-1 are a dangerous duo. Epidemiological data shows that HSV-2 coinfection leads to higher HIV viral loads and larger "reservoirs"—pockets of latent HIV that persist even during antiretroviral therapy (ART).

The traditional explanation was simple: HSV-2 causes inflammation, which recruits more CD4+ T cells (HIV’s primary targets) to the site. However, this doesn't fully explain why coinfected patients on ART experience more frequent HIV "blips" (temporary increases in viral load). This paper investigates the direct molecular mechanisms by which HSV-2 manipulates the host cell's transcriptional machinery to flip the switch from HIV latency to active replication.

Methods

The authors employed a multi-pronged approach using both primary human cells and specialized cell models:

  • Cell Models: They used primary activated CD4+ T cells (from blood and tonsils) and 2D10 cells, a Jurkat-derived reporter line that serves as a gold-standard model for HIV-1 latency.
  • Transcriptomics: To see the "big picture," they performed bulk RNA-Seq on primary T cells and single-cell RNA-Seq (scRNA-Seq) on tonsillar T cells. They used advanced computational tools like Multiscale PHATE for visualization and DREMI/DREVI to map functional relationships between genes across "pseudotime" (the progression of infection).
  • Genetic Manipulation: They used CRISPR/Cas9 to knock out MALAT1 in 2D10 cells to prove its necessity in the reactivation process.
  • Mechanistic Probing: They transfected cells with specific HSV-2 proteins (VP16, ICP0, ICP4) to identify which viral component was responsible for the effect.
  • Epigenetics: Mass spectrometry was used to quantify global changes in histone modifications, specifically looking at marks associated with gene silencing (H3K27me3) and activation (H4 acetylation).

Datasets

  • Bulk RNA-Seq: Data from activated primary human CD4+ T cells from 5 HIV-uninfected donors.
  • scRNA-Seq: Data from human tonsillar CD4+ T cells (capturing T follicular helper cell populations).
  • Public Repository: All sequencing data is deposited in the NCBI Gene Expression Omnibus (GEO) under accession numbers GSE229392, GSE229390, and GSE229391.

Key Insights and Ideas

  • The MALAT1 Lever: The long noncoding RNA MALAT1 is the central player. HSV-2 infection significantly boosts MALAT1 expression. MALAT1 then interacts with the Polycomb Repressive Complex 2 (PRC2), effectively displacing it from the HIV promoter (the LTR).
  • Epigenetic De-repressing: By displacing PRC2, MALAT1 reduces the levels of H3K27me3—a chemical "lock" on the DNA that keeps HIV silent. This releases the epigenetic brakes, allowing HIV to replicate.
  • VP16 as the Trigger: The HSV-2 tegument protein VP16, usually known for activating HSV's own genes, was found to be the specific trigger that upregulates MALAT1 and drives HIV reactivation.
  • The Bystander Effect: Interestingly, the "neighborhood" matters. Even cells that weren't directly infected by HSV-2 (bystanders) showed transcriptional changes—like the downregulation of HIV restriction factors (e.g., APOBEC3G, IL-32)—that make them more hospitable to HIV reactivation.

Key Results

  • Latency Reversal: HSV-2 exposure caused a ~1 log10-fold increase in HIV ltr expression in latency models.
  • Transcriptional Shift: RNA-Seq identified over 7,800 genes upregulated in HSV-2 infected cells, with MALAT1 being a standout candidate.
  • Knockout Impact: Deleting MALAT1 via CRISPR reduced HSV-2-mediated HIV reactivation by approximately 50%, proving it is a major, though not the only, pathway.
  • VP16 Potency: Transfecting cells with VP16 alone was sufficient to significantly upregulate MALAT1 and trigger HIV latency reversal, mimicking the effect of the whole virus.
  • Histone Changes: HSV-2 infection and VP16 transfection led to a measurable decrease in global H3K27me3 and an increase in histone H4 acetylation, indicating a shift toward an open, transcriptionally active chromatin state.

Limitations and Future Work

  • In Vitro vs. In Vivo: The study was conducted entirely in cell culture. While the mechanisms are compelling, they need to be validated in clinical samples from coinfected patients.
  • Partial Abrogation: Since the MALAT1 knockout only reduced reactivation by 50%, other HSV-2-driven pathways are clearly at play. The authors suggest that changes in other restriction factors (like the decrease in IL-32) also contribute.
  • Locus Specificity: The histone analysis was global. Future work should use ChIP-seq to confirm that these epigenetic changes are happening specifically at the HIV ltr integration site.
  • Therapeutic Potential: This pathway identifies MALAT1 or VP16-related interactions as potential targets for "block and lock" strategies to keep HIV latent, or conversely, as tools for "shock and kill" eradication efforts.

Summary updated

Abstract

Herpes simplex virus type 2 (HSV-2) coinfection is associated with increased HIV-1 viral loads and expanded tissue reservoirs, but the mechanisms are not well defined. HSV-2 recurrences result in an influx of activated CD4+ T cells to sites of viral replication and an increase in activated CD4+ T cells in peripheral blood. We hypothesized that HSV-2 induces changes in these cells that facilitate HIV-1 reactivation and replication and tested this hypothesis in human CD4+ T cells and 2D10 cells, a model of HIV-1 latency. HSV-2 promoted latency reversal in HSV-2-infected and bystander 2D10 cells. Bulk and single-cell RNA-Seq studies of activated primary human CD4+ T cells identified decreased expression of HIV-1 restriction factors and increased expression of transcripts including MALAT1 that could drive HIV replication in both the HSV-2-infected and bystander cells. Transfection of 2D10 cells with VP16, an HSV-2 protein that regulates transcription, significantly upregulated MALAT1 expression, decreased trimethylation of lysine 27 on histone H3 protein, and triggered HIV latency reversal. Knockout of MALAT1 from 2D10 cells abrogated the response to VP16 and reduced the response to HSV-2 infection. These results demonstrate that HSV-2 contributes to HIV-1 reactivation through diverse mechanisms, including upregulation of MALAT1 to release epigenetic silencing.
BibTeX
@article{pierce2023hsv,
  author = {Carl A. Pierce and Lip Nam Loh and Holly R. Steach and Natalia Cheshenko and Paula Preston‐Hurlburt and Fengrui Zhang and Stephanie Stransky and Leah Kravets and Simone Sidoli and William M. Philbrick and Michel Nassar and Smita Krishnaswamy and Kevan C. Herold and Betsy C. Herold},
  title = {{HSV-2 triggers upregulation of MALAT1 in CD4+ T cells and promotes HIV latency reversal}},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  doi = {10.1172/jci164317},
}
Figure